Appointment of Executive Director & FDA Pre-Ind Meeting
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Neuroscientific Biopharmaceuticals Ltd. has announced the appointment of Dr. Tony Keating as Executive Director following the resignation of Dougal Thring as chief operating officer. The company has also filed a Pre-Investigation New Drug Application meeting request with the FDA for EmtinB, aimed at treating advanced glaucoma in adults. This meeting is expected to clarify the regulatory requirements for progressing towards an investigational new drug application.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Neuroscientific Biopharmaceuticals Ltd. on 6ix
Earlier from Neuroscientific Biopharmaceuticals
- NSB Receives A$2.2M Research & Development Tax Refund
- Resignation of CEO
- Appointment of CEO
- 2023 Annual Report and Appendix 4E
- Positive treatment effect in MS animal study
Later from Neuroscientific Biopharmaceuticals
- 2024 Annual Report & Appendix 4E
- NeuroScientific to Acquire Leading Stem Cell Technology
- Previous StemSmart Studies Demonstrate Clinical Response
- StemSmart Acquisition Complete
- Experienced Cell Therapy Executive Appointed CEO
Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.
Follow Neuroscientific Biopharmaceuticals